Etienne Schonbach, Leopoldina Fellowship Program Grant No LPDS 2015-14 (F);
Artur Cideciyan, None;
Mohamed Ibrahim, None;
Rupert Strauss, None;
David Birch, 4D Molecular Therapeutics (F), Acucela (C), AGTC (F), AGTC (C), Genentech (C), Ionis Pharmaceuticals (F), Ionis Pharmaceuticals (C), Nacuity (C), NightstaRX (F), NightstaRX (C);
Janet Sunness, None;
Srinivas Sadda, Allergan (F), Allergan (C), Carl Zeiss Meditec (F), Genentech (F), Genentech (C), Iconic (C), Novartis (C), Optos (F), Optos (C), Thrombogenics (C);
Hendrik Scholl, Acucela Inc. (F), Astellas Institute for Regenerative Medicine (C), Boehringer Ingelheim Pharma GmbH & Co. KG (C), Daiichi Sankyo (C), Foundation Fighting Blindness Clinical Research Institute (FFB CRI) (F), Foundation Fighting Blindness Clinical Research Institute (FFB CRI) (R), Genentech Inc./F. Hoffmann-La Roche Ltd (R), Gensight Biologics (C), Genzyme Corp./Sanofi (R), Gerson Lehrman Group (C), Guidepoint (C), Intellia Therapeutics (C), National Centre of Competence in Research (NCCR) Molecular Systems Engineering (University of Basel and ETH Zürich), Swiss National Science Foundation (F), NightstaRx Ltd (F), Novelion Therapeutics Inc (F), QLT, Inc. (F), ReNeuron Group Plc/Ora Inc (R), Shire (C), Shulsky Foundation (F), U.S. Department of Defense USAMRMC TATRC, Fort Meade, Maryland (grant numbers W81-XWH-07-1-0720 and W81XWH-09-2-0189) (F)